Kiromic BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRBP research report →
Price Chart
About the company
Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial intelligence to advance allogeneic cell therapies. The company's core mission involves crafting multi-indication T-cell treatments, specifically engineered to combat solid tumors by leveraging the innate capabilities of Gamma Delta T cells.
- CEO
- Pietro Bersani CPA,
- IPO
- 2020
- Employees
- 44
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on KRBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $214.93K
- P/E
- -0.08
- PEG
- -0.01
- P/S
- 0.00
- P/B
- -0.17
- EV/EBITDA
- -0.57
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 247.82%
- ROIC
- -1200.10%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-23,774,000
- Net Income
- $-26,898,000-26.3%
- EPS
- $-1.03+95.2%
- OCF Growth
- +8.3%
- FCF Growth
- +7.5%
- 52W High
- $3.31
- 52W Low
- $0.05
- 50D MA
- $0.97
- 200D MA
- $1.25
- Beta
- 1.66
- RSI (14)
- 41
- Avg Volume
- 7.89K
No earnings-call transcripts are available for KRBP yet.
- Free Float
- 44.6%
- Shares Outstanding
- 2.65M
- Float Shares
- 1.18M
of shares held by institutions
12 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Zeke Capital Advisors, LLC | 107.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 24 | BERSANI PIETRO | buy | 988 |
| Aug 23, 24 | BERSANI PIETRO | buy | 2,500 |
| Aug 20, 24 | Hungerford Brian | buy | 3,742 |
| Aug 19, 24 | Hungerford Brian | buy | 258 |
| Aug 13, 24 | Hungerford Brian | buy | 2,000 |
| Jun 12, 24 | Misajon Pamela | buy | 410 |
| Jun 12, 24 | Misajon Pamela | buy | 1,200 |
| Jun 13, 24 | Hungerford Brian | buy | 1,000 |
| Jun 11, 24 | NAGEL MICHAEL | buy | 1,000 |
| Jun 10, 24 | Misajon Pamela | buy | 1,701 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KRBP coverage
Recent articles, reports, and earnings notes.
No research on KRBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KRBP report →Gainey McKenna & Egleston Announces the Proposed Class Action Settlement on Behalf of Purchasers of Kiromic BioPharma Inc. common stock - KRBPQ
globenewswire.com · Sep 21
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
businesswire.com · Feb 18
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
businesswire.com · Jan 21
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
businesswire.com · Dec 3
SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews
newsfilecorp.com · Dec 3
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
businesswire.com · Oct 8
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
businesswire.com · Sep 19
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
businesswire.com · Aug 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.